Eosinophil and Anticoagulation in COVID-19 Patients

Sponsor

Bursa Postgraduate Hospital (Other)

Overall Status

Completed

CT.gov ID

NCT04507282

Collaborator

(none)

Enrollment

Location

Actual Duration (Months)

39.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Despite prophylactic anticoagulant treatments, thrombotic complications may develop in patients with Coronavirus disease 2019 (COVID-19). This study aimed to evaluate anti-Factor Xa levels to determine the anticoagulant activity of low molecular weight heparin (LMWH) in COVID-19 patients.

Condition or Disease	Intervention/Treatment	Phase
COVID-19	Drug: LMWH

Study Design

Study Type:

Observational

Actual Enrollment :

80 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi

Actual Study Start Date :

May 15, 2020

Actual Primary Completion Date :

Jul 1, 2020

Actual Study Completion Date :

Jul 15, 2020

Arms and Interventions

Arm	Intervention/Treatment
COVID 19 positive patients	Drug: LMWH COVID 19 positive patients anticogulation level, subprophylactic level and prophylactic level

Arm

Intervention/Treatment

COVID 19 positive patients

Drug: LMWH

COVID 19 positive patients anticogulation level, subprophylactic level and prophylactic level

Outcome Measures

Primary Outcome Measures

subprophylactic anticogulation level [14 days]
<0.2IU/ml

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Inclusion Criteria:

Patients older than 18 years, who were diagnosed with COVID-19 and were administered LMWH,
agreed to participate in the study were included

Exclusion Criteria:

Patients with previous coagulopathy,
continuous indication of anticoagulant therapy (atrial fibrillation (AF), valve disease),
glomerular filtration rate (GFR) <30 mL/min or undergoing dialysis, or with known liver dysfunction were excluded from the study.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Bursa Yüksek İhtisas Hastanesi	Yıldırım		Turkey	16310

Sponsors and Collaborators

Bursa Postgraduate Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Hasan ARI, Medical Doctor of Cardiology, Bursa Postgraduate Hospital

ClinicalTrials.gov Identifier:

NCT04507282

Other Study ID Numbers:

Bursa Postgraduate Hospital

First Posted:

Aug 11, 2020

Last Update Posted:

Aug 18, 2020

Last Verified:

Aug 1, 2020

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Yes

Studies a U.S. FDA-regulated Device Product:

Product Manufactured in and Exported from the U.S.:

Additional relevant MeSH terms:

COVID-19

Study Results

No Results Posted as of Aug 18, 2020